Dosage forms comprising a CETP inhibitors and an HMG-CoA reductase inhibitor

US7897175B2 · kind B2 · utility

Assignee

• Bend Reserch, Inc. · US

Inventors

• Dwayne T. Friesen · Bend, US
• David Keith Lyon · Bend, US
• Douglas Alan Lorenz · Bend, US
• Bruno Hancock · Preston, US
• Timothy J. McDermott · Salem, US
• Ravi M. Shanker · Groton, US

Key dates

• Filing date: Dec 18, 2003
• Grant date: Mar 1, 2011
• Expiry date: Sep 20, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/2081
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A dosage form comprises (1) a solid amorphous dispersion comprising a cholesterol ester transfer protein inhibitor and an acidic concentration-enhancing polymer and (2) an HMG-CoA reductase inhibitor. The solid amorphous dispersion and the HMG-CoA reductase inhibitor are combined in the dosage form so that the solid amorphous dispersion and the HMG-CoA reductase inhibitor are substantially separate from one another in the dosage form.